

// ()
// , ,

E

*

E

(mg/d) (mg/d) (mg/d) E

E

E

HDL-C LDL-C

HDL-C

Lp(a) apoB100 apoAI LDL-C

E

Lp(a)

E

hadtabibi@yahoo.com :

:(

.()

HDL

(PUFA) Polyunsaturated Fatty Acid

E

Food Processor II

Bonferroni (ANOVA)

BMI

± ± ±

Adjusted Bonferroni (ANCOVA)

E ()

PUFA MUFA

ANOVA

()

E

Levene

()

(BMI) Body Mass Index

()

Tamhane

Levene

Bonferroni

(P< /)

()

—

() (P< /)

(Kruskal-Wallis)

E

()

(Friedman)

E

(P< /)

E

$$\cdot (\quad)$$

P< / : - a

P< / : - b

P< / : - c


(P< /)


$$(P_{<} /)$$

.()

Lp(a) apoB100 apoAI

.()





/			
		HDL	()
			SR-BI
		HDL	
		HDL	
		apoAI	(reverse cholestrol transport)
apoAI			.()
.()		HDL	
apoB100			HDL-C
			.() HDL
E		E	
			HDL-C
apoB100	apoB100	/	
			()
	Lp(a)		
			E
.()		E	
Lp(a)			
		LDL-C/HDL-C	
Lp(a)			
	- Lp(a)		HDL-C
-			apo AI
		E	HDL-C
Lp(a)	Lp(a)		
	.()		
	) Lp(a)	apo AI	
		E	
(IL-6) -			

.()

()

()

Lp(a)

.()

Lp(a)

E

HDL-C

LDL-C/HDL-C

.()

E

Lp(a)

HDL-C

)

LDL-C/HDL-C

Lp(a)

(

E

.(-)

E

Shoji .

E

(Niceritrol)

Lp(a)

Lepre

Tri-B3

()

Lp(a)

Goldberg

()...

(Niaspan)

.()

Lp(a)

Lp(a)

REFERENCES

1. Juners P, Khoa TN, Massy ZA, Zingraff J, Labrunie M, Descamps-Latscha B, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: a multicentric study in the Ile de France district. *Nephrol Dial Transplant* 1999; 14: 808-902.
2. Canaud B, Cristol JP, Morena M, Leray-Moragues H, Bosc JY, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. *Blood Purif* 1999; 17: 99-106.
3. Lacour B, Massy Z, Drueke TB. Lipid metabolism. In: Massry SG, Glasscock RJ, editors. *Massry & Glasscock's Textbook of Nephrology*. 4th ed. Philadelphia: Williams & Wilkins. 2001; P: 1346-56.
4. Toborek M, Wasik T, Drozd M, Klin M, Magner-Wrobel K, Kopieczna-Grzebieniak E. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. *Metabolism* 1992; 41: 1229-32.
5. Katzung BG. *Basic & Clinical Pharmacology*. 8th ed. New York: McGraw-Hill. 2001; P: 588-90.
6. Skorecki K, Green J, Brenner BM. Chronic renal failure. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. *Harrison's Principle of Internal Medicine*. 15th ed. New York: McGraw-Hill. 2001; P: 1551-62.
7. Denker BM, Chertow GM, Owen WF. Hemodialysis. In: Brenner BM, editor. *Brenner & Rector's the Kidney*. 6th ed. Philadelphia: W.B. Saunders. 2000; P: 2373-419.
8. Olyaei AJ, Demattos AM, Bennett WM. Prescribing drugs in renal disease. In: Brenner BM, editor. *Brenner & Rector's the Kidney*. 6th ed. Philadelphia: W.B. Saunders. 2000; P: 2632.
9. Hermann WJ, Ward K, Faucett J. The effect of tocopherol on high density lipoprotein cholesterol. *Am J Clin Pathol* 1979; 72: 848-52.
10. Cloarec MJ, Perdriset GM, Lamberdiere FA, Colas-Belcour JF, Sauzieres JP, Neufeld HN, et al. α -Tocopherol: effect on plasma lipoproteins in hypercholesterolemic patients. *Isr J Med Sci* 1987; 23: 869-72.
11. Paolisso G, Gambardella A, Giugliano D, Galzerano D, Amato L, Volpe C, et al. Chronic intake of pharmacological dose of vitamin E might be useful in the therapy of elderly patients with coronary heart disease. *Am J Clin Nutr* 1995; 61: 848-52.
12. Jain SK, Mcvie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type 1 diabetic patients (Abstr.). *J Am Coll Nutr* 1996; 15: 458-61.
13. Karasu D, Ozansoy G, Bozkurt O, Erdogan D, Omeroglu S. Antioxidant and triglyceride-lowering effects of vitamin E associated with the prevention of abnormalities in the reactivity and morphology of aorta from streptozotocin diabetic rats. *Metabolism* 1997; 46: 872-9.
15. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. *Am J Clin Nutr* 1988; 48: 612-9.

16. Rifai N, Bachorik PS, Albers JJ. Lipids, lipoproteins and apoproteins. In: Burtis CA, Ashwood ER, editors. *Tietz Textbook of Clinical Chemistry*. 3rd ed. Philadelphia:W.B. Saunders. 1999; P: 809- 61.
17. Vuilleumier JP, Keller HE, Fidanza F. Vitamin nutriture methodology: Vitamin E. In: Fidanza F, editors. *Nutritional Status Assessment*. 1st ed. London:Chapman & Hall. 1991; P:209-14.
18. Piironen V, Varo P, Syvaola EL, Salminen K, Koivistoinen P. High-performance liquid chromatographic determination of tocopherols and tocotrienols and its application to diets and plasma of finnish men I. Analytical method. *Internat J Vit Nutr Res*. 1984; 54: 35-40.
19. Winer BJ, Brown DR, Michels KM. *Statistical Principles in Experimental Design*. 3rd ed. New York: McGraw-Hill. 1991; P:739-837.
20. Cook RJ, Dunnett CW. Multiple comparisons. In: Armitage P, Cotlon T, editors. *Encyclopedia of Biostatistics*. Chichester: John Wiley & Sons. 1998; P: 2740-2.
21. Munro BH. Selected nonparametric techniques. In: Munro BH, editors. *Statistical Methods for Health Care Research*. 4th ed. Philadelphia : Lippincott. 2001: P:112-5.
22. Siegel S, Castellan NJ. *Nonparametric Statistics for the Behavioral Sciences*. 2nd ed. New York:McGraw–Hill. 1988; P: 206-15.
23. Farrell PM, Roberts RJ. Vitamin E. In: Shils ME, Olson JA, Shike M, editors. *Modern Nutrition in Health and Disease*. 8th ed. Philadelphia: Lea & Febiger. 1994; P: 326-41.
24. Packard CJ, Shepherd J. Metabolic basis of the atherogenic lipoprotein phenotype. In : Gotto AM, Lenfant C, Catapano AL, Paoletti R, editors. *Multiple Risk Factors in Cardiovascular Disease*. Dordrecht: Kluwer Academic Publishers. 1995; P: 289-94.
25. Pritchard KA, Patel ST, Karpen CW, Newman HA, Panganamala RV. Triglyceride-lowering effect of dietary vitamin E in streptozotocin-induced diabetic rats (Abstr.). *Diabetes* 1986; 35: 278-81.
26. Galli F, Varga Z, Balla J, Ferraro B, Canestrari F, Floridi A, et al. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. *Kideny Int* 2001;59[suppl.78]: S 148-54.
27. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. *Atherosclerosis* 2000; 150: 217-24.
28. Leonhardt ETG. Effects of vitamin E on serum cholesterol and triglyceride in hyperlipidemic patients treated with diet and clofibrate. *Am J Clin Nutr* 1978; 31: 100-5.
29. Schwartz PL, Rutherford IM. The effect of tocopherol on high density lipoprotein cholesterol. *Am J Clin Pathol* 1981; 77: 843- 4.
30. Hatam LJ, Kayden GJ. The failure of α -tocopherol supplementation to alter the distribution of lipoprotein cholesterol in normal and hyperlipoproteinemic persons. *Am J Clin Pathol* 1981; 76: 122-3.
31. Kesaniemi YA, Grundy SM. Lack of effect of tocopherol on plasma lipids and lipoproteins in man. *Am J Clin Nutr* 1982; 36: 224-8.

32. Howard DR, Rundell CA, Batsakis JG. Vitamin E does not modify HDL-cholesterol. *Am J Clin Pathol* 1982; 77: 86-9.
33. Serfontein WJ, Ubbink E, Devilliers LS. Further evidence on the effect of vitamin E on the cholesterol distribution in lipoproteins with special reference to HDL subfractions. *Am J Clin Pathol* 1983; 79: 604-6.
34. Stampfer MJ, Willett W, Castell WP, Taylor JO, Fine J, Hennekens CH. Effect of vitamin E on lipids. *Am J Clin Pathol* 1983; 79: 714-6.
35. Chapkin RS, Haberstroh B, Liu T, Holub BJ. Effect of vitamin E supplementation on serum and high density lipoprotein cholesterol in renal patients on maintenance hemodialysis. *Am J Clin Nutr* 1983; 38: 253-6.
36. Kalbfleisch JH, Barboriak JJ, Else BA, Hughes CV, Tristani FE. Alpha-tocopherol supplements and high density lipoprotein cholesterol levels. *Br J Nutr* 1986; 55: 71-77.

E

38. Knopp RH. Clinical profiles of plain versus sustained-release niacin (niaspan) and the physiologic rationale for night time dosing. *Am J Cardiol* 1998; 82: 24U-28U.
39. Goldberg AC. Clinical trial experience with extended- release niacin (niaspan): dose-escalation study. *Am J Cardiol* 1998; 82: 35U- 38U.
40. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (niaspan): a long-term study. *Am J Cardiol* 1998; 82: 74U-81U.
41. Morgan JM, Capuzzi DM, Guyton JR. A new extended- release niacin (niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. *Am J Cardiol* 1998; 82: 29U- 34U.
42. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. *Atherosclerosis* 1992; 95: 69-76.
43. Lepre F, Campbell B, Crane S, Hichman P. Low-dose sustained release nicotinic acid (Tri-B3) and lipoprotein(a). *Am J Cardiol* 1992; 70: 133.
44. Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD, Kashyap M, et al. Equivalent efficacy of a time-release form of niacin (niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. *Metabolism* 1998; 47: 1097-104.
45. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. *Kidney Int* 1999; 56[suppl. 71]: S134- S136.
46. Shoji T, Nishizawa Y, Kawasaki K, Tabata T, Matsushita Y, Inoue T, et al. Effects of the nicotinic acid analogue niceritrol on lipoprotein Lp(a) and coagulation-fibrinolysis status in patients with chronic renal failure on hemodialysis. *Nephron* 1997; 77: 112-3.
47. Komaratat P, Chupukcharoen N, Wilairat P. Effect of vitamin E on cholesterol plasma lipoprotein distribution and metabolism in rabbit. *Internat J Vit Nutr Res* 1985; 55: 167-71.

48. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. *Kidney Int* 1992; 41: 1394-9.
49. Wanner C, Zimmermann J, Quaschnig T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. *Kidney Int* 1997; 52[suppl.62]: S53-S55.
50. Nishizawa Y, Shoji T, Kawagishi T, Morii H. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. *Kidney Int* 1997; 52[suppl.62]: S90-S92.
51. Kwiterovich PO. The antiatherogenic role of high-density lipoprotein cholesterol. *Am J Cardiol* 1998; 82: 13Q- 21Q.
52. Kashyap ML. Mechanistic studies of high-density lipoproteins. *Am J Cardiol* 1998; 82: 42U- 48U.
53. Dahlen GH, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. *Clin Genet* 1997; 52: 272-80.
54. Tzanatos H, Fourtounas C, Agrogannis B, Chondros K, Dalamangas A, Bossiolis B, et al. Alterations of plasma lipoprotein(a) concentration. Do they arise from the haemodialysis procedure? *Nephrol Dial Transplant* 1996; 11: 1491-2.
55. Yang WS, Kim SB, Min WK, Park S, Lee MS, Park JS. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients (Abstr.). *Nephrol Dial Transplant* 1995; 10: 1668-71.
56. Scanu AM. Atherothrombogenicity of lipoprotein(a): the debate. *Am J Cardiol* 1998; 82: 26Q-33Q.
57. Tetta C, Biasiol S, Schiavon R, Inguaggiato P, David S, Panichi V, et al. An overview of haemodialysis and oxidant stress. *Blood Purif* 1999; 17: 118-26.